Drug intelligence / Profile preview

flupirtine + interferon beta-1b

Development stage: Preclinical
Lead developer: Theriva Biologics
Modality: Small Molecules, Recombinant Proteins and Enzymes
Administration: Oral, Subcutaneous

Overview

A combination of flupirtine, a non-opioid analgesic with neuroprotective properties, and interferon beta-1b, an immunomodulatory therapy for multiple sclerosis. This combination aims to provide both neuroprotection and immunomodulation for patients with multiple sclerosis, particularly those with optic neuritis. Research suggests that the combination may improve visual function better than either agent alone.

Targets

GABRR (GABA-A receptor subunit rho)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))NMDAR (Glutamate receptor ionotropic, NMDA)MHC I (MHC class I})

Beyond the preview

Go deeper on flupirtine + interferon beta-1b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on flupirtine + interferon beta-1b.